A review of emerging tyrosine kinase inhibitors as durable treatment of neovascular age-related macular degeneration
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A review of emerging tyrosine kinase inhibitors as durable treatment of neovascular age-related macular degeneration
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 28, Issue 3, Pages 203-211
Publisher
Informa UK Limited
Online
2023-10-05
DOI
10.1080/14728214.2023.2259790
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disengagement and loss to follow-up in intravitreal injection clinics for neovascular age-related macular degeneration
- (2023) Rebecca Jones et al. EYE
- Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial
- (2023) Ryusaburo Mori et al. JAPANESE JOURNAL OF OPHTHALMOLOGY
- Trends and disparities in disease burden of age-related macular degeneration from 1990 to 2019: Results from the global burden of disease study 2019
- (2023) Bo Jiang et al. Frontiers in Public Health
- Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
- (2022) Chris Liang et al. Molecular Therapy-Oncolytics
- Suprachoroidal versus Intravitreal Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema
- (2022) Yousra Gamal Zakaria et al. Clinical Ophthalmology
- A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration
- (2022) Stephen H. Poor et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Recent Advances in Age-Related Macular Degeneration Therapies
- (2022) Marie Fabre et al. MOLECULES
- Practical implementation of a q4–q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel
- (2022) Clare Bailey et al. EYE
- Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions
- (2022) Viral S. Kansara et al. JOURNAL OF CONTROLLED RELEASE
- Pharmacokinetics of intravitreal macromolecules: scaling between rats and rabbits
- (2021) Amir Sadeghi et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Biomechanics of suprachoroidal drug delivery: From benchtop to clinical investigation in ocular therapies
- (2021) Shelley E. Hancock et al. Expert Opinion on Drug Delivery
- The pro‐inflammatory response of macrophages regulated by acid degradation products of poly(lactide‐co‐glycolide) nanoparticles
- (2021) Shufang Ma et al. ENGINEERING IN LIFE SCIENCES
- Age-Related Macular Degeneration
- (2021) Catherine J. Thomas et al. MEDICAL CLINICS OF NORTH AMERICA
- Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib Suspension Via Ocular and Systemic Disposition in Rabbits
- (2021) Viral S. Kansara et al. Translational Vision Science & Technology
- Correlation Analysis of Target Selectivity and Side Effects of FDA‐Approved Kinase Inhibitors**
- (2021) Omer Bayazeid et al. ChemistrySelect
- New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
- (2021) Prem Patel et al. Journal of Clinical Medicine
- A Novel Eye Drop Formulation for Potential Treatment of Neovascular Age-Related Macular Degeneration
- (2021) Wen-Chia Huang et al. Translational Vision Science & Technology
- APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration
- (2020) Michael N. Cohen et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Systematic review: non-adherence and non-persistence in intravitreal treatment
- (2020) Christoph Ehlken et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Non-adherence or non-persistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review
- (2020) Mali Okada et al. OPHTHALMOLOGY
- CONSEQUENCES OF LAPSES IN TREATMENT WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN ROUTINE CLINICAL PRACTICE
- (2020) Tyler E. Greenlee et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Anti-vascular endothelial growth factor in neovascular age-related macular degeneration – a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems
- (2020) Robert P. Finger et al. BMC Ophthalmology
- Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach
- (2019) Zohar Habot-Wilner et al. ACTA OPHTHALMOLOGICA
- The suprachoroidal space as a route of administration to the posterior segment of the eye
- (2018) Bryce Chiang et al. ADVANCED DRUG DELIVERY REVIEWS
- The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration
- (2018) Christopher M. Adams et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial
- (2018) Antonia M. Joussen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Characterization of Poor Visual Outcomes of Neovascular Age-related Macular Degeneration Treated with Anti–Vascular Endothelial Growth Factor Agents
- (2018) Chu Luan Nguyen et al. OPHTHALMOLOGY
- Circumferential flow of particles in the suprachoroidal space is impeded by the posterior ciliary arteries
- (2016) Bryce Chiang et al. EXPERIMENTAL EYE RESEARCH
- METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- (2016) Leah N. Kim et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor
- (2015) Y. Zhao et al. ONCOLOGIST
- Clinical Evaluation of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections in Subjects with Neovascular Age-Related Macular Degeneration
- (2015) Karl G. Csaky et al. OPHTHALMOLOGY
- Molecular pathogenesis of retinal and choroidal vascular diseases
- (2015) Peter A. Campochiaro PROGRESS IN RETINAL AND EYE RESEARCH
- CLINICAL EVALUATION OF PAZOPANIB EYE DROPS IN HEALTHY SUBJECTS AND IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- (2014) Rishi Singh et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
- (2014) Wan Ling Wong et al. Lancet Global Health
- Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration
- (2013) Ronald Danis et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Clinical Pharmacology of Axitinib
- (2013) Ying Chen et al. CLINICAL PHARMACOKINETICS
- Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors
- (2012) M. McTigue et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Hydrogels in drug delivery: Progress and challenges
- (2008) Todd R. Hoare et al. POLYMER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started